Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 10/20 | 0.66 |
| ▸ | IKZF2 | Q9UKS7 | 10/20 | 0.62 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.57 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.57 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26270738 | 0.93 | CRBN (0.70) | CRBNIKZF2GSPT1DDB1IKZF3 | |
| SCHEMBL25568967 | 0.92 | CRBN (0.68) | CRBNIKZF2GSPT1DDB1IKZF3 | |
| SCHEMBL31628426 | 0.91 | CRBN (0.67) | CRBNIKZF2GSPT1DDB1IKZF3 | |
| SCHEMBL27350115 | 0.91 | CRBN (0.66) | CRBNIKZF2GSPT1 | |
| SCHEMBL15128601 | 0.91 | CRBN (0.69) | CRBNIKZF2GSPT1DDB1IKZF3 | |
| SCHEMBL25469611 | 0.91 | CRBN (0.69) | CRBNIKZF2GSPT1DDB1IKZF3 | |
| SCHEMBL31444586 | 0.90 | CRBN (0.67) | CRBNIKZF2GSPT1DDB1IKZF3 | |
| SCHEMBL31444757 | 0.89 | CRBN (0.66) | CRBNIKZF2GSPT1DDB1IKZF3 | |
| SCHEMBL31444715 | 0.89 | CRBN (0.69) | CRBNIKZF2GSPT1DDB1IKZF3 | |
| SCHEMBL29188614 | 0.89 | CRBN (0.66) | CRBNIKZF2GSPT1DDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023186069-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023115149-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023274390-A1 | BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF | 杭州和正医药有限公司 | 2023-01-05 | — | — | WO | disclosed |
| US-20210220391-A1 | PROTEOLYSIS TARGETING CHIMERIC MOLECULES (PROTACS) WITH FUNCTIONAL HANDLES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220391-A1 | PROTEOLYSIS TARGETING CHIMERIC MOLECULES (PROTACS) WITH FUNCTIONAL HANDLES AND USES THEREOF | CRBN, PSMA6, PSMA3 | CRBN 1/4885IKZF2 901/4885GSPT1 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.